CSTL Earnings Date: Nov 5, 2026 (Estimated) — Castle Biosciences, Inc.
NASDAQ · Healthcare · Diagnostics & Research
Updated
When is CSTL's next earnings date?
Castle Biosciences, Inc. (CSTL) is expected to report Q3 2026 earnings on Thursday, November 5, 2026 at 4:00 PM ET (after market close); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.35 on revenue of $92.8M.
How did CSTL do in its last earnings report?
In its most recent report on Jul 30, 2026 (Q2 2026), Castle Biosciences, Inc. posted EPS of -$0.07 versus the -$0.41 estimate, a beat of 82.9%. Revenue was $103.5M against a $86.6M estimate. The stock's 1-day post-earnings move was +4.5%.
How much does CSTL stock move after earnings?
CSTL beat EPS estimates in 8 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 13.7% (up or down) in the day after earnings.
About Castle Biosciences, Inc.
Castle Biosciences, Inc. functions as a commercial-stage diagnostics firm, with its primary objective being the provision of both diagnostic and prognostic testing services, specifically targeting various dermatological cancers. Their flagship product, DecisionDx-Melanoma, represents an advanced multi-gene expression profile (GEP) assay engineered to assess the probability of metastasis in patients afflicted with invasive cutaneous melanoma. In addition to their leading solution, the company has created several other specialized, proprietary tests. Among these is DecisionDx-UM, a GEP test tailored to forecast the risk of metastasis for individuals with uveal melanoma, a less common malignancy of the eye. Another key offering is DecisionDx-SCC, a distinctive 40-gene expression profile test that utilizes a patient's unique tumor biology to predict their specific risk of squamous cell carcinoma metastasis, particularly for those presenting with recognized risk factors. Moreover, they offer DecisionDx DiffDx-Melanoma and myPath Melanoma, both proprietary GEP tests employed to assist in the accurate diagnosis of ambiguous pigmented lesions. These specialized testing services are provided by Castle Biosciences to patients predominantly through their healthcare providers. The organization commenced operations in 2007 and maintains its corporate headquarters in Friendswood, Texas.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-07-30 | Q2 2026 | -0.41 | -0.07 | +82.93% | $103.5M | ✅ Beat | +4.52% | +13.74% | +25.05% |
| 2026-05-06 | Q1 2026 | -0.50 | -0.49 | +2.00% | $83.7M | ✅ Beat | -22.26% | -26.67% | -15.11% |
| 2026-02-26 | Q4 2025 | -0.24 | -0.08 | +66.67% | $87.0M | ✅ Beat | -7.25% | -12.45% | -26.19% |
| 2025-11-03 | Q3 2025 | -0.44 | -0.02 | +95.45% | $83.0M | ✅ Beat | +21.70% | +33.67% | +51.64% |
| 2025-02-27 | Q4 2024 | 0.04 | 0.32 | +700.00% | $86.3M | ✅ Beat | -14.24% | -18.55% | -21.12% |
| 2024-11-04 | Q3 2024 | -0.06 | 0.08 | +233.33% | $85.8M | ✅ Beat | -7.40% | +0.42% | -5.23% |
| 2024-05-02 | Q1 2024 | -0.33 | -0.09 | +72.73% | $73.0M | ✅ Beat | +6.52% | +6.92% | +2.45% |
| 2024-02-28 | Q4 2023 | -0.54 | -0.10 | +81.48% | $66.1M | ✅ Beat | -25.95% | -12.01% | -9.18% |
Showing last 8 quarters.